[18F]-FACBC PET Imaging for Prostate Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring metastatic cancer are challenging due to difficulties in obtaining accurate and reproducible imaging, particularly for prostate cancer, where existing PET tracers like FDG-PET have low sensitivity and specificity.
Innovation Solution
The use of [18F]-FACBC for PET imaging, involving administration protocols that include injecting a detectable amount into the right arm, raising it overhead during scanning, and acquiring images 3-5 minutes post-injection, allows for improved detection and monitoring of metastatic or recurrent cancer by comparing sequential PET scan images.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FDG-PET is used for cancer imaging, then the imaging can be performed with established protocols, but the sensitivity and specificity for prostate cancer and some other cancer types is low
Solution Approach 1:
The patent changes the chemical parameter of the imaging tracer from FDG to FACBC. FACBC is an amino acid analog that targets amino acid transporters, which are overexpressed in prostate cancer and other malignancies. This parameter change (molecular structure and transport mechanism) resolves the contradiction by providing high diagnostic accuracy for prostate cancer specifically, while acknowledging that different cancer types may require different tracer optimizations.
2Measurement precision
If multiple PET scan images are obtained at different time points for monitoring metastatic cancer, then the detection sensitivity improves, but the difficulty in obtaining accurate and reproducible images increases
Solution Approach 1:
The patent establishes preliminary standardized protocols for FACBC administration and PET imaging that must be followed consistently across multiple time points. This includes standardized injection procedures, uptake times, and scanning parameters. By pre-establishing these protocols, the patent reduces the complexity and variability inherent in obtaining reproducible images at multiple time points, thereby resolving the contradiction between improved detection sensitivity and imaging protocol complexity.
3Loss of time
If [18F]-FACBC is administered and imaging is performed immediately, then the imaging time is reduced, but the tracer uptake and diagnostic quality may be insufficient
Solution Approach 1:
The patent optimizes the uptake time parameter for FACBC to approximately 3-5 minutes post-injection, which is significantly shorter than conventional PET tracers. This parameter optimization allows sufficient tracer accumulation in tumor tissue while minimizing total imaging time, thereby resolving the contradiction between reduced imaging time and maintained detection sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables sensitive detection of prostate cancer recurrence with improved diagnostic accuracy and efficiency, balancing imaging time and cost considerations, and effectively localizes tumour tissue using PET/MRI or PET/CT scanners.
Implementation Method 1
Fluciclovine (18F) injection, also known as [18F]-FACBC, FACBC, or anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid, is a synthetic amino acid imaging agent which is taken up specifically by amino acid transporters and is used for positron emission tomography (PET)
Data Source
AI summary
The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.